Fig. 4: Upfront resectable (left panels) and borderline resectable (right panels) in the central tertiary centre multidisciplinary team resectability assessment compared with resectability assessment in local hospitals done before systemic therapy and recruitment to the RAXO trial.

a and b RAS and BRAF wild type patients. c and d RAS mutated type patients. e and f BRAF mutated type patients.